Edition:
India

Tonix Pharmaceuticals Holding Corp (TNXP.OQ)

TNXP.OQ on NASDAQ Stock Exchange Global Market

3.73USD
17 Jan 2018
Change (% chg)

$-0.14 (-3.62%)
Prev Close
$3.87
Open
$3.85
Day's High
$3.85
Day's Low
$3.67
Volume
4,642
Avg. Vol
15,365
52-wk High
$9.38
52-wk Low
$2.85

Select another date:

Tue, Jan 9 2018

BRIEF-Tonix Pharmaceuticals Appoints Jessica Morris As CEO

* TONIX PHARMACEUTICALS APPOINTS JESSICA MORRIS AS CHIEF OPERATING OFFICER Source text for Eikon: Further company coverage:

BRIEF-Tonix Pharmaceuticals Completes Positive Pre-Ind Meeting With FDA For TNX-102 SL

* TONIX PHARMACEUTICALS COMPLETES POSITIVE PRE-IND MEETING WITH FDA FOR TNX-102 SL (CYCLOBENZAPRINE HCI SUBLINGUAL TABLETS) AS A CLINICAL CANDIDATE FOR AGITATION IN ALZHEIMER’S DISEASE

BRIEF-Tonix Pharmaceuticals Q3 loss per share $0.77

* Tonix Pharmaceuticals reports third quarter 2017 financial results and provides programs update

BRIEF-Tonix Pharma reports outcomes from CMC guidance meeting with FDA on Tonmya

* Tonix Pharmaceuticals reports outcomes from U.S. FDA breakthrough therapy CMC guidance meeting of Tonmya® (cyclobenzaprine hci sublingual tablets) for PTSD

BRIEF-Tonix Pharmaceuticals enters into purchase agreement, registration rights agreement with Lincoln Park Capital Fund

* On Sept. 28 co entered into purchase agreement, registration rights agreement with Lincoln Park Capital Fund LLC

BRIEF-Tonix Pharmaceuticals receives European patent for the active ingredient in Tonmya

* Tonix Pharmaceuticals receives European patent for the active ingredient in Tonmya® (cyclobenzaprine hcl sublingual tablets) Source text for Eikon: Further company coverage:

BRIEF-Tonix Pharmaceuticals elects Margaret Smith Bell to the Board of Directors

* Tonix Pharmaceuticals elects Margaret Smith Bell to the Board of Directors Source text for Eikon: Further company coverage:

BRIEF-Tonix Pharmaceuticals presents additional phase 2 clinical results, ongoing phase 3 trial design of Tonmya at 2017 Military Health System Research Symposium

* Tonix Pharmaceuticals presented additional phase 2 clinical results in military-related PTSD and design of ongoing phase 3 trial at the 2017 Military Health System Research Symposium

BRIEF-Tonix Pharmaceuticals to present at Military Health System Research Symposium

* Tonix Pharmaceuticals to present additional phase 2 clinical results and design of ongoing phase 3 trial in military-related ptsd at the 2017 military health system research symposium Source text for Eikon: Further company coverage:

BRIEF-Tonix Pharmaceuticals Holding reports Q2 loss per share $0.65

* Tonix Pharmaceuticals reports second quarter 2017 financial results and provides programs update

Select another date: